CenterBook Partners LP grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 125.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,654 shares of the medical research company's stock after purchasing an additional 14,835 shares during the quarter. CenterBook Partners LP owned approximately 0.10% of Bio-Rad Laboratories worth $6,492,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Headlands Technologies LLC grew its holdings in Bio-Rad Laboratories by 64.1% in the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after buying an additional 139 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its position in Bio-Rad Laboratories by 8.8% in the first quarter. Ontario Teachers Pension Plan Board now owns 2,217 shares of the medical research company's stock worth $540,000 after purchasing an additional 179 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Bio-Rad Laboratories by 5.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 203,180 shares of the medical research company's stock worth $49,487,000 after purchasing an additional 11,313 shares during the period. ASR Vermogensbeheer N.V. acquired a new stake in Bio-Rad Laboratories in the first quarter worth approximately $461,000. Finally, XTX Topco Ltd lifted its position in Bio-Rad Laboratories by 134.3% in the first quarter. XTX Topco Ltd now owns 4,567 shares of the medical research company's stock worth $1,112,000 after purchasing an additional 2,618 shares during the period. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Stock Down 1.3%
Shares of NYSE BIO traded down $3.34 during mid-day trading on Friday, reaching $246.31. The company had a trading volume of 227,859 shares, compared to its average volume of 331,897. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.43 and a current ratio of 5.99. The stock has a market capitalization of $6.70 billion, a PE ratio of -3.23 and a beta of 0.95. The stock's 50 day moving average is $238.15 and its 200-day moving average is $267.35.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. The firm had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business's quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.30 earnings per share. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on BIO shares. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 13th. UBS Group reduced their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Citigroup reduced their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Royal Bank Of Canada reduced their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research note on Monday, June 9th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $324.25.
Check Out Our Latest Stock Analysis on BIO
Bio-Rad Laboratories Company Profile
(
Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Further Reading
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
